Artificial Antigen-Presenting Cells for CAR T Cell Gene Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of CAR T cells is hindered by the high cost and limited supply of paramagnetic beads and RetroNectin, which are essential for activating and expanding T cells, and the beads' limited ability to conjugate with antibodies for immune cell activation.
Innovation Solution
The use of artificial antigen presenting cells (aAPC) with a heparin binding domain (HBD), anti-CD3 single chain antibodies, and anti-CD28 single chain antibodies to activate T cells and bind viral vectors, facilitating effective gene transfer, thereby reducing costs and increasing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If paramagnetic beads and RetroNectin are used for T cell activation and gene transfer, then T cell activation and expansion are achieved, but the cost increases and supply is limited
Solution Approach 1:
The patent replaces expensive, limited-supply paramagnetic beads and RetroNectin with a cost-effective, renewable artificial antigen-presenting cell system. The aAPCs can be produced in bulk and reused, eliminating the need for costly disposable beads and enabling scalable CAR T cell production without supply constraints.
Solution Approach 2:
The patent creates artificial antigen-presenting cells that replicate the essential functions of natural antigen-presenting cells and beads. The aAPCs express CD3 and CD28 ligands to activate T cells and display heparin-binding domains to concentrate viral vectors, providing a renewable copy of the activation mechanism that overcomes the limitations of original bead-based systems.
2Reliability
If paramagnetic beads are used to activate T cells, then T cell activation is achieved, but the ability to conjugate with additional antibodies is limited due to small size
Solution Approach 1:
The patent divides the activation function into separate modular components on the aAPC surface: CD3 ligands for T cell receptor engagement, CD28 ligands for co-stimulation, and heparin-binding domains for viral vector concentration. This segmentation allows each function to be optimized independently and enables flexible customization by adding or modifying specific antibody conjugates on the aAPC surface.
Solution Approach 2:
The artificial antigen-presenting cells serve multiple functions simultaneously: they activate T cells through CD3 and CD28 ligands, concentrate viral vectors through heparin-binding domains, and can be customized with additional antibody conjugates for targeting specific T cell subsets or enhancing specific activation pathways. This multi-functionality replaces the limited single-function beads.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a cost-effective, renewable, and efficacious alternative for CAR T cell production by enhancing T cell activation and gene transfer efficiency, reducing reliance on expensive materials and expanding T cell proliferation.
Implementation Method 1
the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer
Implementation Method 2
Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo
Data Source
AI summary
Disclosed herein are methods of producing chimeric antigen receptor (CAR) T cells using substrates, such as artificial antigen presenting cells, containing on a surface a a heparin binding domain (HBD), anti-CD3 single chain antibodies, anti-CD28 single chain antibodies (scFv), and optionally anti-41BBL antibodies. Anti-CD3 and Anti-CD28 scFvs bind and activate expanding T cells ex vivo, while the Heparin Binding Domain binds the viral vector, thereby bringing the T cells into close proximity with virus for effective gene transfer. This is a less costly, renewable, modifiable, and efficacious alternative to coated beads and RetroNectin® for gene transfer.